Becker RC, Gore JM, Rubison M, Lambrew C, Tiefenbrunn A, French WJ, Rogers W
Thrombosis Research Center, Clinical Trials Section, University of Massachusetts Medical Center, Worcester, MA 01655.
J Thromb Thrombolysis. 1995;2(3):231-237. doi: 10.1007/BF01062715.
Background: In epidemiologic studies, excessive body weight, independent of other risk factors, portends a poor prognosis among patients with coronary artery disease experiencing acute myocardial infarction (MI). At least one recent study has suggested that patients of excessive body weight when receiving thrombolytic therapy are often under-dosed, potentially reducing early coronary arterial patency and adversely affecting in-hospital clinical outcome. Concern has also been raised that body weight may influence treatment utilization, delays, and complication rates. Despite these concerns, the association between body weight and patient outcome following coronary thrombolysis has received limited attention. Methods/Results: Demographic, procedural, and outcome data from patients with MI were collected at 1073 United States hospitals participating in The National Registry of Myocardial Infarction from 1990 through 1994. Among 350,755 patients with MI enrolled, 87,688 (25.1%) were treated with tissue plasminogen activator (t-PA). Divided into body weight tertiles, 23.5% of patients were less than 70 kg (low weight), 36.8% were 70-85 kg (moderate weight), and 37.5% were greater than 85 kg (high weight). Patients of low weight were older (p < 0.001), received treatment later (p < 0.001), and were less likely to undergo cardiac catheterization, coronary angioplasty, or bypass surgery (p < 0.001) than moderate- or high-weight patients. Low-weight patients also experienced minor bleeding, major bleeding, recurrent MI, and death more often (p < 0.001). Adjusted for age, low body weight was independently associated with in-hospital mortality. Despite receiving a lower dose of t-PA per kg body weight, high-weight patients had a low incidence of cardiogenic shock, recurrent MI, death, and hemorrhagic complications.When high-weight women and men were compared, several interesting observations emerged. Mortality was increased twofold in women (6.8% vs. 3.0; p < 0.001), even adjusting for their older age. Despite being at increased risk, women were less likely than their male counterparts to undergo cardiac catheterization (p = 0.001) or bypass surgery (p = 0.008). Conclusions: The National Registry of Myocardial Infarction provides a unique resource for assessing health care trends in the United States. Our findings suggest that low body weight is associated with increased in-hospital morbidity and mortality. They also suggest that current dosing strategies for t-PA administration are probably adequate for high-weight patients. The excessive mortality and limited use of in-hospital interventions among high-weight women deserve further study to address gender-related differences in disease processes, as well as potential bias or discrimination.
在流行病学研究中,超重(独立于其他危险因素)预示着冠心病急性心肌梗死(MI)患者预后不良。至少最近一项研究表明,超重患者接受溶栓治疗时剂量往往不足,这可能会降低早期冠状动脉通畅率,并对住院临床结局产生不利影响。也有人担心体重可能会影响治疗的使用、延误及并发症发生率。尽管存在这些担忧,但体重与冠状动脉溶栓后患者结局之间的关联却很少受到关注。
方法/结果:1990年至1994年期间,在美国1073家参与国家心肌梗死注册研究的医院收集了心肌梗死患者的人口统计学、治疗过程及结局数据。在登记的350755例心肌梗死患者中,87688例(25.1%)接受了组织型纤溶酶原激活剂(t-PA)治疗。按体重三分位数划分,23.5%的患者体重低于70千克(低体重),36.8%的患者体重在70 - 85千克之间(中等体重),37.5%的患者体重超过85千克(高体重)。与中等体重或高体重患者相比,低体重患者年龄更大(p < 0.001),接受治疗时间更晚(p < 0.001),且接受心脏导管插入术、冠状动脉血管成形术或搭桥手术的可能性更小(p < 0.001)。低体重患者发生轻微出血、严重出血、心肌梗死复发及死亡的情况也更常见(p < 0.001)。校正年龄后,低体重与住院死亡率独立相关。尽管每千克体重接受的t-PA剂量较低,但高体重患者的心源性休克、心肌梗死复发、死亡及出血并发症发生率较低。比较高体重女性和男性时,出现了一些有趣的发现。即使校正了年龄,女性的死亡率仍增加了两倍(6.8%对3.0%;p < 0.001)。尽管风险增加,但女性接受心脏导管插入术(p = 0.001)或搭桥手术(p = 0.008)的可能性低于男性。
国家心肌梗死注册研究为评估美国的医疗保健趋势提供了独特的资源。我们的研究结果表明,低体重与住院发病率和死亡率增加有关。这些结果还表明,目前t-PA给药的剂量策略可能适用于高体重患者。高体重女性过高的死亡率以及住院干预措施的有限使用值得进一步研究,以解决疾病过程中与性别相关的差异,以及潜在的偏见或歧视问题。